Head-to-head comparison of PT-141 (Bremelanotide) and Kisspeptin-10 for sexual health optimization. Compare mechanisms, onset, dosing, and who each peptide is best suited for.
Bremelanotide — melanocortin agonist studied for sexual function.
Hypothalamic neuropeptide studied for reproductive hormone regulation and libido.
Side-by-Side Comparison
| Property | PT-141 | Kisspeptin-10 |
|---|---|---|
| Category | Melanocortin | Melanocortin |
| Mechanism | Melanocortin receptor agonist (MC3R and MC4R) that activates central dopaminergic pathways involved in sexual arousal — acting directly on the hypothalamus to generate desire independent of vascular mechanisms. | Neuropeptide that activates the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, stimulating the hypothalamic-pituitary-gonadal (HPG) axis to increase LH, FSH, and downstream testosterone and estradiol production. |
| Half-Life | ~2.7 hours | ~30 minutes |
| Typical Dosage | 1–2 mg SC or intranasal, 1–2 hours before activity | 1–10 mcg/kg SC, protocol varies |
| Primary Use | Sexual arousal and desire, erectile function, HSDD treatment (FDA approved for women) | HPG axis stimulation, testosterone optimization, reproductive hormone support, fertility |
| Onset | 30–60 minutes; peak effect at 1–2 hours | LH/testosterone elevation measurable within 1–2 hours; hormonal axis effects build over weeks |
| Stacks Well With | Kisspeptin-10, MT-2 | PT-141, Sermorelin, CJC-1295 |
Overview
Melanocortin receptor agonist (MC3R and MC4R) that activates central dopaminergic pathways involved in sexual arousal — acting directly on the hypothalamus to generate desire independent of vascular mechanisms.
Neuropeptide that activates the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, stimulating the hypothalamic-pituitary-gonadal (HPG) axis to increase LH, FSH, and downstream testosterone and estradiol production.
Applications & Benefits
- FDA-approved for hypoactive sexual desire disorder (HSDD) in women as Vyleesi
- Central mechanism works regardless of vascular health
- Fast onset — 30–60 minutes to effect
- Effective in both men and women across clinical studies
- Does not require continuous use — on-demand dosing
- Addresses root hormone axis rather than direct arousal pathways
- Increases endogenous testosterone and LH in research models
- Potential fertility support applications (HPG axis optimization)
- Clean safety profile in human clinical studies
- Works at the hormonal foundation level, not just symptomatic relief
PT-141 vs Kisspeptin-10: Bottom Line
PT-141 and Kisspeptin-10 operate through completely different pathways, making them tools for different problems rather than direct competitors. PT-141 is the acute arousal compound — fast onset, central dopaminergic mechanism, FDA-validated for women's HSDD. It works regardless of testosterone levels and is best for on-demand use. Kisspeptin-10 is a hormonal axis compound — it stimulates the GPG axis to drive LH and testosterone elevation, addressing the upstream hormonal foundation of sexual function. For acute arousal and performance, PT-141 is the first choice. For hormonal optimization and fertility-adjacent protocols, Kisspeptin-10 is the appropriate tool. Advanced protocols use both: PT-141 for direct performance support while Kisspeptin-10 works at the hormonal foundation level.
Compare Other Peptides
Mix and match any of the 19 peptides in our catalog for a custom side-by-side comparison.
Build New Comparison